| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Apr 2025 - 30 Sept 2025 | 31 Oct 2025 | 36 | 60% | 27% | 13% | 38% |
| 01 Oct 2024 - 31 Mar 2025 | 30 Apr 2025 | 35 | 52% | 39% | 9% | 48% |
| 01 Apr 2024 - 30 Sept 2024 | 30 Oct 2024 | 30 | 74% | 21% | 4% | 26% |
| 01 Oct 2023 - 31 Mar 2024 | 29 Apr 2024 | 28 | 71% | 27% | 2% | 26% |
| 01 Apr 2023 - 30 Sept 2023 | 27 Oct 2023 | 24 | 80% | 16% | 4% | 18% |
| 01 Oct 2022 - 31 Mar 2023 | 28 Apr 2023 | 26 | 73% | 20% | 6% | 26% |
| 01 Apr 2022 - 30 Sept 2022 | 28 Oct 2022 | 24 | 74% | 21% | 5% | 25% |
| 01 Oct 2021 - 31 Mar 2022 | 28 Apr 2022 | 24 | 78% | 17% | 6% | 22% |
| 01 Apr 2021 - 30 Sept 2021 | 27 Oct 2021 | 24 | 82% | 13% | 5% | 16% |
| 01 Oct 2020 - 31 Mar 2021 | 30 Apr 2021 | 22 | 87% | 10% | 3% | 12% |
| 01 Apr 2020 - 30 Sept 2020 | 30 Oct 2020 | 33 | 66% | 23% | 11% | 29% |
| 01 Oct 2019 - 31 Mar 2020 | 30 Apr 2020 | 26 | 75% | 19% | 4% | 26% |
| 01 Apr 2019 - 30 Sept 2019 | 25 Oct 2019 | 23 | 84% | 14% | 2% | 11% |
| 01 Oct 2018 - 31 Mar 2019 | 26 Apr 2019 | 37 | 55% | 32% | 13% | 43% |
| 01 Apr 2018 - 30 Sept 2018 | 26 Oct 2018 | 45 | 50% | 37% | 13% | 46% |
| 01 Oct 2017 - 31 Mar 2018 | 27 Apr 2018 | 45 | 48% | 34% | 18% | 50% |
This information is as reported by the business, and responses are in their own words.
Standard payment terms
Standard contractual terms for goods and services is 60 days from invoice date. For intercompany accounts the standard contractual terms is 60 days
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
In the current reporting period the company implemented a new ERP system which resulted in a higher % of payments being made late over the cutover and subsequent period. We expect to return to normal payment practices during the next reporting period.
Maximum contractual payment period agreed
60
The main point of contact for disputes is the Victrex Shared Service team, based at Victrex Technology Centre, Thornton Cleveleys, UK. When an invoice is disputed, the supplier will be notified directly at the earliest opportunity by either a member of the Shared Service team, or by the person who raised the purchase order. To resolve a dispute, the supplier is required to provide any missing information, a corrected invoice or a credit note. As communicated to suppliers, Victrex’s Purchase Order number must be quoted on all invoices to be paid.
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
INVIBIO LIMITED is a leading company in the healthcare market, specializing in advanced biomaterials and medical devices. Founded in 1980, the company is based in Thornton Cleveleys, Lancashire, with a registered office at Hillhouse International, Hillhouse Technology Enterprise Zone.
The company is committed to sustainability and has implemented various initiatives to reduce its carbon footprint and promote responsible business practices. These include reducing waste and water usage, using renewable energy sources, and promoting recycling.
INVIBIO LIMITED's main product is PEEK-OPTIMA, a high-performance polymer used in medical implants and devices. This material is biocompatible, lightweight, and has excellent mechanical properties, making it suitable for use in a wide range of medical applications.
The company's sustainability efforts also extend to its products, with PEEK-OPTIMA being recyclable and produced using a sustainable manufacturing process. This not only benefits the environment but also contributes to the overall cost-effectiveness of the product.
INVIBIO LIMITED has a team of experienced and knowledgeable individuals leading the company, including CEO Professor Andrew Metcalfe, who has over 30 years of experience in the healthcare industry. The company also has a global network of distributors and partners, ensuring the availability of their products and services worldwide.
For more information on INVIBIO LIMITED and their sustainability program, products, and services, please visit their website at www.invibio.com. The company is dedicated to making a positive impact on the healthcare industry while also prioritizing the environment and sustainability.
Proud of your payment record? Show your live score on your own site:
<iframe src="https://paymentcheck.co.uk/badge/04088050" width="240" height="72" style="border:0" title="PaymentCheck Score" loading="lazy"></iframe>